SCHEMBL2376252

SCHEMBL2376252

COc1ccc(C=CC(=O)N(Cc2ccc(N3CCOCC3)nc2)[C@@H](Cc2ccccc2)C(=O)N2CCC(Cc3ccccc3)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
POLB P06746 1/20 0.42
RAB9A P51151 1/20 0.42
P2RX7 Q99572 1/20 0.41
BCHE P06276 3/20 0.41
MAOA P21397 3/20 0.41
ACHE P22303 3/20 0.41
MAOB P27338 3/20 0.41
TACR2 P21452 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 1/20 0.39
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2376256 1.00 LMNA (0.42) LMNASMN1; SMN2POLBRAB9AP2RX7
SCHEMBL2376249 1.00 LMNA (0.42) LMNASMN1; SMN2POLBRAB9AP2RX7
SCHEMBL2374610 0.93 TRPM8 (0.42) SMN1; SMN2RAB9AKDM4EMAPTMEN1
SCHEMBL2374607 0.93 TRPM8 (0.42) SMN1; SMN2RAB9AKDM4EMAPTMEN1
SCHEMBL2374615 0.93 TRPM8 (0.42) SMN1; SMN2RAB9AKDM4EMAPTMEN1
SCHEMBL2373756 0.93 LMNA (0.49) LMNAP2RX7BCHEMAOAACHE
SCHEMBL2373754 0.93 LMNA (0.49) LMNAP2RX7BCHEMAOAACHE
SCHEMBL2373752 0.93 LMNA (0.49) LMNAP2RX7BCHEMAOAACHE
SCHEMBL2374025 0.90 GAA (0.39) LMNASMN1; SMN2P2RX7BCHEMAOA
SCHEMBL2374023 0.90 GAA (0.39) LMNASMN1; SMN2P2RX7BCHEMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US claimed
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 LMNA 1347/4885SMN1; SMN2 4567/4885POLB 1882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.